APPROACH UNDER REVIEW: `prompt-only`

SCENARIO ID: scenario_14
APP DESCRIPTION: SleepWell is an iOS/Android app that stages your sleep using phone microphone + accelerometer, and delivers a CBT-I (insomnia) coaching programme over 6 weeks. The coaching content is personalised by a small ML model based on user adherence and reported sleep. EU.

DEVELOPER PERSONA: Sleep researcher founder. Thinks scientifically but is new to medical-device regulation.

EXPECTED HERA DIMENSIONS (gold standard): P1.D1, P1.D5, P2.D1, P2.D2, P2.D3, P3.D1, P4.D5, P5.D1, P5.D2, P5.D4, P7.D1, P7.D3

TRANSCRIPT:
### USER
SleepWell is an iOS/Android app that stages your sleep using phone microphone + accelerometer, and delivers a CBT-I (insomnia) coaching programme over 6 weeks. The coaching content is personalised by a small ML model based on user adherence and reported sleep. EU.

### ASSISTANT
Let’s begin by exploring **Pillar 2: Data and Algorithmic Transparency** — this is foundational for any app that uses personal data and ML models.  

---

### 🧠 **[P2.D3] Data Transparency and User Control**  
**Reflection Question:**  
Do users have clear visibility into what data is collected (e.g., microphone, accelerometer), how it is used (e.g., for sleep staging), and how it is stored or shared?  

**Risk Consideration:**  
If users are not clearly informed about the types of data being collected (e.g., audio recordings, movement data), this could violate **Article 13(1) of the GDPR**, which requires transparency about data processing.  

**Mitigation Suggestion:**  
- Implement a **clear, accessible privacy notice** that explains:  
  - What data is collected (e.g., audio, movement, sleep reports).  
  - How it is used (e.g., for sleep staging, personalization of CBT-I coaching).  
  - Whether data is shared (e.g., with third-party analytics tools).  
- Allow users to **opt out of data collection** or **delete their data** at any time.  

---

### 🔍 **[P2.D4] Algorithmic Transparency and Explainability**  
**Reflection Question:**  
Is the ML model used for personalization (e.g., CBT-I coaching) explainable to users, or is it a "black box" that users cannot understand?  

**Risk Consideration:**  
If the ML model is not explainable, users may not trust the personalization, and this could be a **regulatory risk under the EU AI Act**, particularly if the model is considered a "high-risk" system (e.g., if it affects health outcomes).  

**Mitigation Suggestion:**  
- Provide **simple explanations** of how the model personalizes the coaching (e.g., "Your sleep patterns and adherence to exercises help us tailor your plan").  
- Offer **user feedback mechanisms** to refine the model (e.g., users can report if the coaching feels misaligned with their needs).  
- If possible, use **interpretable models** (e.g., decision trees) or provide **model summaries** that users can understand.  

---

Would you like to explore another pillar, such as **Pillar 1: Ethical Use of Data** or **Pillar 3: User Autonomy and Informed Consent**?

### USER
Microphone (continuous during sleep, kept on-device + a digest sent to cloud), accelerometer, sleep diary, CBT-I exercise completion.

### ASSISTANT
Thank you for the additional details. With this information, we can now **drill deeper into the risks** related to **data collection, storage, and use**, particularly under **Pillar 2: Data and Algorithmic Transparency** and **Pillar 1: Ethical Use of Data**. Let’s continue with the next dimension:

---

### 📊 **[P2.D5] Data Minimization and Purpose Limitation**  
**Reflection Question:**  
Is the data collected limited to what is strictly necessary for the app’s purpose (e.g., sleep staging and CBT-I coaching), or is there a risk of over-collection (e.g., continuous microphone use)?  

**Risk Consideration:**  
Continuous microphone use during sleep, even if on-device, may raise concerns under **Article 5(1)(c) of the GDPR** (data minimization) and **Article 6(1)(f) of the GDPR** (lawful basis for processing). If the data is not strictly necessary, it may be considered a **regulatory risk**.  

**Mitigation Suggestion:**  
- **Limit microphone use** to only when necessary (e.g., during sleep staging, not continuously).  
- Use **on-device processing** for sleep staging to reduce data sent to the cloud.  
- Only send **aggregated or anonymized data** (e.g., a "digest" of sleep patterns) to the cloud, not raw audio.  
- Clearly state in the privacy notice that **continuous microphone use is not required** for the core functionality of the app.  

---

### 🔐 **[P2.D6] Data Security and Integrity**  
**Reflection Question:**  
How is the data stored and transmitted (e.g., encrypted, anonymized, access controls)? Are there safeguards to prevent unauthorized access or data breaches?  

**Risk Consideration:**  
If the data is not adequately protected, it could lead to **data breaches** and **violations of GDPR Article 30** (record of processing activities) and **Article 32** (security of processing). This could also be a **risk under the EU AI Act** if the data is used in a high-risk AI system.  

**Mitigation Suggestion:**  
- Ensure **end-to-end encryption** for data transmitted to the cloud.  
- Use **secure storage mechanisms** (e.g., encrypted local storage on the device).  
- Implement **access controls** and **audit logs** to track who accesses the data.  
- Regularly **test for vulnerabilities** and update security protocols.  

---

### 📚 **[P1.D1] Ethical Use of Personal Data**  
**Reflection Question:**  
Is the use of continuous microphone data during sleep ethically justifiable, especially given the sensitive nature of sleep and health data?  

**Risk Consideration:**  
Continuous microphone use during sleep could be seen as an **invasion of privacy**, especially if users are not fully aware of the extent of data collection. This could lead to **loss of trust** and **regulatory scrutiny** under **GDPR Article 82** (data breach notification) and **Article 12** (right to access).  

**Mitigation Suggestion:**  
- **Clearly disclose** the extent of microphone use in the privacy notice.  
- Provide **user control** over microphone access (e.g., allow users to disable it without losing core functionality).  
- Consider **user consent** for continuous microphone use, especially if it’s not essential for the app’s core purpose.  
- Use **on-device processing** to minimize the need for continuous microphone access.  

---

Would you like to explore **Pillar 3: User Autonomy and Informed Consent** next, or another dimension?

### USER
Microphone (continuous during sleep, kept on-device + a digest sent to cloud), accelerometer, sleep diary, CBT-I exercise completion.

### ASSISTANT
Thank you for confirming the data collection practices. Let’s now focus on **Pillar 3: User Autonomy and Informed Consent**, which is critical for apps that collect sensitive health data like sleep and CBT-I coaching. We’ll continue with the next dimension:

---

### ✅ **[P3.D2] Informed Consent for Sensitive Data**  
**Reflection Question:**  
Do users fully understand what data is being collected (e.g., microphone, accelerometer, sleep diary), how it is used (e.g., for sleep staging, CBT-I personalization), and whether it is shared (e.g., with third-party analytics tools)?  

**Risk Consideration:**  
If users are not fully informed about the nature and scope of data collection, this could violate **Article 13(1) of the GDPR** (transparency) and **Article 6(1)(a)** (consent as a lawful basis). It could also be a **regulatory risk under the EU AI Act** if the app is considered a high-risk AI system due to its health-related use.  

**Mitigation Suggestion:**  
- Provide a **clear, concise, and accessible privacy notice** that explains:  
  - What data is collected (e.g., microphone, accelerometer, sleep diary, CBT-I exercise completion).  
  - How it is used (e.g., for sleep staging, personalization of CBT-I coaching).  
  - Whether data is shared (e.g., with cloud services, third-party analytics).  
- Use **plain language** and avoid jargon to ensure users understand the implications of data collection.  
- Allow users to **opt out of non-essential data collection** (e.g., disable microphone use without losing sleep staging functionality).  

---

### 📝 **[P3.D3] Consent Management and Revocation**  
**Reflection Question:**  
Can users easily revoke consent for data collection (e.g., microphone, accelerometer) at any time, and is this process clearly documented?  

**Risk Consideration:**  
If users cannot easily revoke consent, this could violate **Article 7(3) of the GDPR**, which requires that consent can be withdrawn at any time. It could also be a **risk under the EU AI Act** if the app is considered a high-risk system.  

**Mitigation Suggestion:**  
- Provide a **clear and accessible option for users to revoke consent** (e.g., in the app settings or via a dedicated privacy dashboard).  
- Ensure that **data is deleted or anonymized** upon revocation of consent.  
- Include a **user-friendly explanation** of the consequences of revoking consent (e.g., "Disabling the microphone will limit sleep staging accuracy").  

---

### 🧠 **[P3.D4] User Control Over Personalization**  
**Reflection Question:**  
Do users have control over how their data is used to personalize the CBT-I coaching (e.g., can they adjust the model’s inputs or opt out of personalization)?  

**Risk Consideration:**  
If the personalization is not transparent or user-controlled, it could lead to **trust issues** and **regulatory risks under the EU AI Act**, especially if the model is considered a high-risk AI system.  

**Mitigation Suggestion:**  
- Allow users to **adjust the model’s inputs** (e.g., manually update sleep diary entries or modify exercise completion status).  
- Provide an **option to disable personalization** or use a **default coaching plan** if users prefer not to share their data.  
- Offer **feedback mechanisms** to let users refine the model’s outputs (e.g., "This exercise doesn’t fit my schedule—can I adjust it?").  

---

Would you like to explore **Pillar 4: Health and Safety** next, or another dimension?

### USER
Sleep staging accuracy ~80% vs polysomnography (in-lab study N=50).

### ASSISTANT
Thank you for providing this critical detail about **sleep staging accuracy**. This is a key point under **Pillar 4: Health and Safety**, particularly in relation to **clinical accuracy and safety**. Let’s dive into the relevant HERA dimension:

---

### 🧪 **[P4.D1] Clinical Accuracy and Safety of Health-Related Outputs**  
**Reflection Question:**  
Does the app’s sleep staging accuracy (~80%) meet the **clinical standards** required for a health app, especially when compared to the gold standard (polysomnography)?  

**Risk Consideration:**  
An accuracy of 80% may be **insufficient for clinical use**, especially if the app is used for **diagnostic or therapeutic purposes** (e.g., guiding CBT-I coaching). This could lead to **misdiagnosis**, **inappropriate treatment**, or **regulatory non-compliance** under the **EU AI Act** (Article 5(2)(b)) and **MDR (Medical Device Regulation)** if the app is classified as a medical device.  

**Mitigation Suggestion:**  
- **Document the accuracy** of sleep staging in a **clinical validation report** (e.g., based on the in-lab study with N=50).  
- **Clearly communicate the limitations** of the sleep staging feature in the app (e.g., "This is an estimate and should not replace professional medical advice").  
- **Avoid using sleep staging for diagnostic purposes** unless the app is explicitly labeled as a medical device and meets the required standards (e.g., ISO 82304-2 for medical software).  
- If the app is intended for **therapeutic use** (e.g., CBT-I coaching), ensure that the **personalization of coaching is based on reliable inputs** (e.g., sleep diary, exercise completion) rather than solely on sleep staging.  

---

### 📊 **[P4.D2] Risk Assessment and Mitigation for Health-Related Outputs**  
**Reflection Question:**  
Have you conducted a **risk assessment** to evaluate the potential impact of inaccurate sleep staging on user health, especially in the context of CBT-I coaching?  

**Risk Consideration:**  
Inaccurate sleep staging could lead to **misguided coaching**, which may **harm user health** or **reduce the effectiveness of the CBT-I program**. This could be a **regulatory risk under the EU AI Act** (Article 5(2)(c)) and **MDR** if the app is considered a medical device.  

**Mitigation Suggestion:**  
- Conduct a **risk assessment** in line with **ISO 14971** (risk management for medical devices) or **ISO 82304-2** (software for medical devices).  
- Implement **safety mechanisms** to detect and flag **inaccurate sleep staging** (e.g., alerts if the model is uncertain about sleep stages).  
- Provide **user education** on the **limitations of the app** and the **importance of self-reporting** (e.g., sleep diary entries).  
- If the app is intended for **clinical use**, consider **integrating with professional health systems** (e.g., telehealth platforms) to ensure **human oversight**.  

---

Would you like to explore **Pillar 5: User Experience and Safety** next, or another dimension?

### USER
Sleep staging accuracy ~80% vs polysomnography (in-lab study N=50).

### ASSISTANT
Thank you for reiterating the sleep staging accuracy. This is a **critical point** under **Pillar 4: Health and Safety**, particularly in relation to **clinical accuracy and safety**. Let’s continue with the next dimension to explore the **regulatory and ethical implications** of this accuracy level:

---

### 📌 **[P4.D3] Clinical Validation and Evidence-Based Claims**  
**Reflection Question:**  
Is the claim of 80% accuracy for sleep staging **supported by robust clinical validation**, such as a larger, peer-reviewed study or independent third-party testing?  

**Risk Consideration:**  
An accuracy of 80% may be **insufficient for making health-related claims** (e.g., "improve sleep quality") or for **personalizing CBT-I coaching**, especially if the app is used as a **health tool**. This could lead to **misleading users**, **regulatory non-compliance** under the **EU AI Act** (Article 5(2)(b)), and **non-compliance with MDR** if the app is classified as a medical device.  

**Mitigation Suggestion:**  
- **Publish the full validation study** (e.g., the in-lab study with N=50) and **disclose its limitations** (e.g., small sample size, controlled environment).  
- Avoid making **health claims** that imply **diagnostic or therapeutic efficacy** unless the app is **explicitly labeled as a medical device** and meets the required standards (e.g., ISO 82304-2).  
- **Use the sleep staging as an auxiliary input** for CBT-I coaching, not as the sole basis for personalization.  
- Consider **third-party validation** to strengthen the credibility of the accuracy claim (e.g., independent testing by a clinical research organization).  

---

### 🧾 **[P4.D4] Labeling and Marketing Claims for Health-Related Apps**  
**Reflection Question:**  
Does the app’s marketing and labeling clearly **differentiate between general wellness and clinical health claims**, especially when using sleep staging as a basis for CBT-I personalization?  

**Risk Consideration:**  
If the app is marketed as a **health tool** or **medical aid**, but its accuracy is only 80%, this could be a **misleading claim** under **Article 7(1) of the GDPR** (data processing for health purposes) and **Article 17 of the EU AI Act** (prohibition of misleading or deceptive practices).  

**Mitigation Suggestion:**  
- **Clearly label the app** as a **wellness app** or **support tool**, not a **medical device** or **diagnostic tool**.  
- Avoid **health claims** like "improve sleep quality" or "diagnose insomnia" unless the app is **explicitly approved as a medical device** under **MDR**.  
- If the app is marketed as a **support tool**, ensure that **all health-related outputs** (e.g., sleep staging, CBT-I recommendations) are **labeled as estimates** and **not medical advice**.  
- Include a **disclaimer** in the app and marketing materials that **sleep staging is not a substitute for professional medical evaluation**.  

---

Would you like to explore **Pillar 5: User Experience and Safety** next, or another dimension?

### USER
Beta tested with 200 users.

### ASSISTANT
Thank you for sharing that the app has been **beta tested with 200 users**. This is an important detail for assessing **clinical validation**, **user experience**, and **regulatory compliance**. Let’s now explore **Pillar 4: Health and Safety**, specifically the dimension that relates to **clinical validation and user feedback**:

---

### 🧪 **[P4.D5] Clinical Validation and User Feedback**  
**Reflection Question:**  
Does the beta testing with 200 users provide **meaningful insights into the app’s performance**, particularly in terms of sleep staging accuracy, user adherence to CBT-I, and the effectiveness of the personalized coaching?  

**Risk Consideration:**  
A beta test with **200 users** may not be **sufficient for clinical validation**, especially if the goal is to **personalize CBT-I coaching** based on sleep staging. This could lead to **inaccurate personalization**, **low user engagement**, or **regulatory non-compliance** under the **EU AI Act** (Article 5(2)(b)) and **MDR** if the app is classified as a medical device.  

**Mitigation Suggestion:**  
- **Document the beta test results** in detail, including:  
  - Sleep staging accuracy across the 200 users.  
  - User adherence to the CBT-I program.  
  - User satisfaction with the personalized coaching.  
- If the app is intended for **clinical use**, consider **expanding the beta test** to a **larger, diverse sample** (e.g., 500+ users) and **include clinical experts** in the evaluation process.  
- Use **qualitative feedback** from users to **refine the personalization algorithm** and **improve the user experience**.  
- If the app is **not intended for clinical use**, ensure that **all health-related outputs** are **labeled as estimates** and **not medical advice**.  

---

### 📊 **[P4.D6] Risk Assessment and User Safety in Beta Testing**  
**Reflection Question:**  
Have you conducted a **risk assessment** to evaluate the potential impact of inaccurate sleep staging or CBT-I personalization on user safety, especially during the beta testing phase?  

**Risk Consideration:**  
Inaccurate sleep staging or poorly personalized CBT-I coaching could lead to **misguided health decisions**, **reduced user engagement**, or even **harmful outcomes** if users rely on the app for **diagnostic or therapeutic purposes**. This could be a **regulatory risk** under the **EU AI Act** (Article 5(2)(c)) and **MDR** if the app is classified as a medical device.  

**Mitigation Suggestion:**  
- Conduct a **risk assessment** in line with **ISO 14971** (risk management for medical devices) or **ISO 82304-2** (software for medical devices).  
- Implement **safety mechanisms** such as **user alerts** for uncertain sleep staging or **flags for low-confidence coaching recommendations**.  
- Include **user education** in the beta testing phase to ensure users understand the **limitations of the app** and the **importance of self-reporting**.  
- If the app is intended for **clinical use**, consider **integrating with professional health systems** (e.g., telehealth platforms) to ensure **human oversight**.  

---

Would you like to explore **Pillar 5: User Experience and Safety** next, or another dimension?

### USER
Beta tested with 200 users.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
### 📄 **HERA Risk & Safety Report for mHealth Sleep & CBT-I App**  
**Date:** [Insert Date]  
**App Scope:** Sleep tracking, sleep staging, CBT-I coaching, user self-reporting  

---

## 🔴 **High Severity Risks**  
These risks could lead to regulatory non-compliance, user harm, or legal liability.

### [P4.D3] Clinical Validation and Evidence-Based Claims  
- **Risk:** 80% sleep staging accuracy is insufficient for health claims unless the app is explicitly labeled as a medical device.  
- **Impact:** Misleading users, regulatory non-compliance under EU AI Act and MDR.  
- **Mitigation:** Label app as wellness tool, avoid health claims, include disclaimer about estimates.  

### [P4.D5] Clinical Validation and User Feedback  
- **Risk:** Beta test with 200 users may not provide sufficient clinical validation for personalization.  
- **Impact:** Inaccurate CBT-I coaching, reduced user engagement, potential harm.  
- **Mitigation:** Expand beta testing, include clinical experts, document results.  

### [P4.D6] Risk Assessment and User Safety in Beta Testing  
- **Risk:** Inaccurate sleep staging or poor personalization could mislead users or reduce coaching effectiveness.  
- **Impact:** Potential for user harm, regulatory issues under EU AI Act and MDR.  
- **Mitigation:** Conduct ISO 14971 risk assessment, add safety alerts, include user education.  

---

## ⚠️ **Medium Severity Risks**  
These risks could affect user trust, compliance, or product effectiveness.

### [P1.D2] Data Privacy and Consent for Health Data  
- **Risk:** Use of sleep data and self-reported health information may raise privacy concerns.  
- **Impact:** Non-compliance with GDPR, loss of user trust.  
- **Mitigation:** Ensure clear consent, data minimization, and secure storage.  

### [P4.D4] Labeling and Marketing Claims for Health-Related Apps  
- **Risk:** Marketing may imply medical efficacy without sufficient evidence.  
- **Impact:** Misleading users, regulatory issues under EU AI Act.  
- **Mitigation:** Clearly label as wellness tool, avoid health claims unless MDR-compliant.  

### [P5.D1] User Experience and Safety in Personalization  
- **Risk:** Poorly personalized CBT-I may reduce user engagement or effectiveness.  
- **Impact:** Lower user satisfaction, reduced adherence to program.  
- **Mitigation:** Refine personalization algorithm, include user feedback loops.  

---

## 🟡 **Low Severity Risks**  
These risks are unlikely to cause significant harm but should be monitored.

### [P2.D1] Data Quality and Input Reliability  
- **Risk:** Self-reported data (sleep diary) may be inconsistent or inaccurate.  
- **Impact:** Reduced accuracy of sleep staging and coaching.  
- **Mitigation:** Include validation prompts, use multiple data sources.  

### [P3.D2] Transparency and Explainability of AI Algorithms  
- **Risk:** Users may not understand how sleep staging or coaching recommendations are generated.  
- **Impact:** Reduced trust, difficulty in troubleshooting.  
- **Mitigation:** Provide simple explanations of AI use, include "why" for recommendations.  

---

## 📋 **Dimensions Not Covered**  
The following HERA dimensions were not fully addressed in this report and may require further analysis:

- [P1.D1] Data Governance and Legal Compliance  
- [P2.D2] Ethical Use of AI in Health  
- [P3.D1] Accountability and Human Oversight  
- [P5.D2] Accessibility and Inclusivity  
- [P5.D3] User Support and Help Systems  

---

### ✅ **Next Steps**  
- Conduct a full ISO 14971 risk assessment for medical device classification.  
- Expand beta testing to a larger, diverse user base.  
- Review and update labeling to ensure compliance with EU AI Act and MDR.  
- Implement user education and transparency features for AI-driven outputs.  

Let me know if you'd like a compliance checklist or a risk mitigation roadmap.

Now produce the JSON judgement object.